Table 1. Clinical characteristics of patients with pulmonary mucormycosis.
| Variables | Total (n=20) | No surgery (n=9) | Surgery (n=11) | P value |
|---|---|---|---|---|
| Age, years | 54.0 (37.0–66.5) | 62.0 (55.0–69.0) | 43.0 (17.0–54.0) | 0.018 |
| Male sex | 11 (55.0) | 5 (55.6) | 6 (54.5) | 1.0 |
| BMI, kg/m2 | 20.8 (18.8–25.6) | 25.5 (18.2–27.4) | 20.7 (19.4–21.4) | 0.171 |
| Comorbidities | ||||
| Diabetes mellitus | 6 (30.0) | 3 (33.3) | 3 (27.3) | 1.0 |
| Hypertension | 5 (25.0) | 3 (33.3) | 2 (18.2) | 0.795 |
| Chronic pulmonary disease | 2 (10.0) | 2 (22.2) | 0 (0) | 0.369 |
| Chronic kidney disease | 1 (5.0) | 1 (11.1) | 0 (0.0) | 0.918 |
| Hematologic disease* | 14 (70.0) | 6 (66.7) | 8 (72.7) | 1.0 |
| Solid organ malignancy | 3 (15.0) | 1 (11.1) | 2 (18.2) | 1.0 |
| HSCT | 4 (20.0) | 2 (22.2) | 2 (18.2) | 1.0 |
| Solid organ transplantation | 4 (20.0) | 2 (22.2) | 2 (18.2) | 1.0 |
| Immunosuppressant drugs | ||||
| Steroid | 8 (40.0) | 4 (44.4) | 4 (36.4) | 1.0 |
| Steroid dose, mg | 40.0 (12.5–77.5) | 12.5 (5.0–55.0) | 55.0 (40.0–77.5) | 0.243 |
| Steroid duration, days | 33.5 (23.5–56.5) | 56.5 (39.5–83.0) | 23.5 (18.5–29.0) | 0.021 |
| Other immunosuppressants | 6 (30.0) | 4 (44.4)** | 2 (18.2)*** | 0.433 |
Values are number (%) or median (interquartile range). *, hematological diseases include acute myeloid leukemia (n=6), acute lymphoblastic leukemia (n=1), chronic lymphoblastic leukemia (n=1), biphenotypic leukemia (acute myeloid leukemia and acute lymphoblastic leukemia) (n=2), lymphoma (n=2), aplastic anemia (n=1), and Langerhans cell histiocytosis (n=1); **, tacrolimus/mycophenolate mofetil (2/1,000 mg/day), tacrolimus (0.5 mg/day), tacrolimus (4 mg/day), and cyclosporine (250 mg/day) were each used in one patient; ***, tacrolimus/everolimus (1/2 mg/day) and tacrolimus (1.5 mg/day) were each used in one patient. BMI, body mass index; HSCT, hematopoietic stem cell transplantation.